SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (323)1/17/2003 5:16:54 PM
From: Icebrg  Read Replies (1) of 631
 
Rick

I just thought that I should mention the claims that J&J made recently (well at a Business Review in September - slide 407).

According to them they have achieved a 75 % improvement on the PASI score for 82 % of the patients on Remicade and an even higher 90 % with their experimental mAb CNTO 1275 (Medarex descendant). In the latter case n was however a paltry 10, so circumstances may still have wreaked havoc with the results. But 70, 80 or 90. Those are outstanding results.

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News